Small Pharma Inc (TSX-V:DMT) announced that it will present at Canaccord Genuity (TSX:CF, LSE:CF)’s 41st Annual Growth Conference on Tuesday 10 August at 8.30am Eastern Time.
The presentation will be led by its chief executive Peter Rands and its chief scientific and medical officer Dr Carol Routledge.
READ: Small Pharma accelerates Phase I/II trial for psychedelics-based depression treatment
A link to the live webcast presentation and a replay will be made available on the “Events” section of the neuropharmaceutical company’s investor relations page.
Small Pharma’s lead candidate SPL026 is currently being trialled in a Phase I/IIa randomized-controlled clinical trial for Major Depressive Disorder in the UK.
Topline data readout of the Phase IIa proof of concept data is anticipated in the first half of 2022.